Clinical Trials Browser

Multiple Myeloma × venetoclax × 90 days × Clear all

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03844048 2026-03-20

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

165 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05530421 2026-02-23

SELVEDge

Phase 2 Recruiting

33 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05391750 2026-02-17

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Phase 1 Active not recruiting

7 enrolled

Plasma cell

Multiple Myeloma

NCT03123029 2026-01-30

Expanded Access to Venetoclax

Available

LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

SELVEDge

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Expanded Access to Venetoclax